Role of Enzyme SMYD3 Clarified in Prostate Cancer Progression

Study renews interest in SMYD3 as a drug target for prostate cancer

Prostate cancer is the most common cancer in men other than skin cancer, and more than 288,000 new cases are diagnosed every year, according to the American Cancer Society. The disease’s fatality rate has decreased by more than half since the 1990s, but there is still room for progress—especially in treating or preventing advanced, metastatic disease, which is much more likely to be fatal. A new paper published in Science Advances clarifies how an enzyme called SMYD3 may be involved in prostate cancer’s progression to a more dangerous and aggressive stage. The enzyme’s newly confirmed role makes it a prime potential drug target for preventing metastatic disease. The open-access article is titled “The SMYD3-MAP3K2 Signaling Axis Promotes Tumor Aggressiveness and Metastasis in Prostate Cancer.”

Login Or Register To Read Full Story